Personalis Q2 2025 Earnings Report

Personalis EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.25
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Personalis Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $20.12 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Personalis Announcement Details

• Quarter: Q2 2025
• Date: 8/6/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 6, 2025
• Conference Call Time: 5:00PM ET

Personalis (NASDAQ:PSNL) (NASDAQ:PSNL) is a leading provider of advanced genomic sequencing and analytics solutions focused on precision immuno-oncology. Founded in 2011 and headquartered in Menlo Park, California, the company operates CAP-accredited and CLIA-certified laboratories in the United States and China. Personalis leverages next-generation sequencing (NGS) technologies to generate high-resolution genomic data that inform cancer immunotherapy research, biomarker discovery, and the development of personalized cancer vaccines.

The company’s core offerings include the ImmunoID NeXT™ platform, which integrates whole-exome and transcriptome sequencing with proprietary immunogenomic analytics to characterize the tumor and its microenvironment. Through products such as the neoantigen characterization engine (NeXT Engine™) and the ACE™ Pan-Cancer Panel, Personalis provides comprehensive profiling of tumor mutational burden, HLA typing, neoantigen prediction and immune repertoire sequencing. These services support pharmaceutical and biotechnology customers in clinical trial design, patient stratification and biomarker validation for novel immunotherapies.

Personalis serves a global client base across North America, Asia and Europe, partnering with leading academic institutions, contract research organizations and major pharmaceutical companies to advance precision medicine initiatives. The company’s leadership team is led by Chair and CEO Dr. Jia Li, a genomic sequencing pioneer with experience at the Broad Institute and Illumina, and COO Dr. David Daly, former head of oncology biomarker development at Thermo Fisher Scientific. Together, they guide Personalis’s strategic growth in immuno-oncology genomics, supporting the industry’s shift toward data-driven, individualized cancer treatment approaches.